Aura Biosciences, Inc. Operating Lease Cost
Aura Biosciences, Inc. (AURA) reported Operating Lease Cost of $867.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-11
- Aura Biosciences, Inc. operating lease, cost for the quarter ending 2026-06-30 was $867.00K, a 0.00% change year-over-year.
- Aura Biosciences, Inc. operating lease, cost for the quarter ending 2026-03-31 was $867.00K, a 0.00% change year-over-year.
- Aura Biosciences, Inc. operating lease, cost for the quarter ending 2025-12-31 was $866.00K, a 0.12% decline year-over-year.
- Aura Biosciences, Inc. operating lease, cost for the quarter ending 2025-09-30 was $867.00K, a 0.00% change year-over-year.
- Aura Biosciences, Inc. operating lease, cost for fiscal 2025 was $3.47M, a 1.23% decline from fiscal 2024.
- Aura Biosciences, Inc. operating lease, cost for fiscal 2024 was $3.51M, a 0.23% decline from fiscal 2023.
- Aura Biosciences, Inc. operating lease, cost for fiscal 2023 was $3.52M, a 87.17% increase from fiscal 2022.
- Aura Biosciences, Inc. operating lease, cost for fiscal 2022 was $1.88M, a 258.59% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $867.00K 10-Q · filed 2026-08-11 | $1.73M 10-Q · filed 2026-08-11 | $2.60M derived: sum of 3 quarters · filed 2026-08-11 | $3.47M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $867.00K 10-Q · filed 2026-05-11 | $1.73M derived: sum of 2 quarters · filed 2026-05-11 | $2.60M derived: sum of 3 quarters · filed 2026-05-11 | $3.47M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $866.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.73M derived: sum of 2 quarters · filed 2026-03-30 | $2.60M derived: sum of 3 quarters · filed 2026-08-11 | $3.47M 10-K · filed 2026-03-30 |
| 2025-09-30 | $867.00K 10-Q · filed 2025-11-13 | $1.73M derived: sum of 2 quarters · filed 2026-08-11 | $2.60M 10-Q · filed 2025-11-13 | $3.47M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $867.00K 10-Q · filed 2026-08-11 | $1.73M 10-Q · filed 2026-08-11 | $2.60M derived: sum of 3 quarters · filed 2026-08-11 | $3.47M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $867.00K 10-Q · filed 2026-05-11 | $1.73M derived: sum of 2 quarters · filed 2026-05-11 | $2.60M derived: sum of 3 quarters · filed 2026-05-11 | $3.47M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $867.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.73M derived: sum of 2 quarters · filed 2026-03-30 | $2.60M derived: sum of 3 quarters · filed 2026-03-30 | $3.51M 10-K · filed 2026-03-30 |
| 2024-09-30 | $867.00K 10-Q · filed 2025-11-13 | $1.73M derived: sum of 2 quarters · filed 2025-11-13 | $2.64M 10-Q · filed 2025-11-13 | $3.48M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $867.00K 10-Q · filed 2025-08-13 | $1.78M 10-Q · filed 2025-08-13 | $2.61M derived: sum of 3 quarters · filed 2025-08-13 | $3.49M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $868.00K 10-Q · filed 2025-05-15 | $1.74M derived: sum of 2 quarters · filed 2025-05-15 | $2.62M derived: sum of 3 quarters · filed 2025-05-15 | $3.50M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $876.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $1.76M derived: sum of 2 quarters · filed 2025-03-24 | $2.64M derived: sum of 3 quarters · filed 2025-03-24 | $3.52M 10-K · filed 2025-03-24 |
| 2023-09-30 | $880.00K 10-Q · filed 2024-11-12 | $1.76M derived: sum of 2 quarters · filed 2024-11-12 | $2.64M 10-Q · filed 2024-11-12 | $3.52M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $881.00K 10-Q · filed 2024-08-08 | $1.76M 10-Q · filed 2024-08-08 | $2.64M derived: sum of 3 quarters · filed 2024-08-08 | $3.33M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $881.00K 10-Q · filed 2024-05-09 | $1.76M derived: sum of 2 quarters · filed 2024-05-09 | $2.45M derived: sum of 3 quarters · filed 2024-05-09 | $2.61M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $878.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $1.57M derived: sum of 2 quarters · filed 2024-03-27 | $1.73M derived: sum of 3 quarters · filed 2024-03-27 | $1.88M 10-K · filed 2024-03-27 |
| 2022-09-30 | $692.00K 10-Q · filed 2023-11-09 | $847.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.00M 10-Q · filed 2023-11-09 | $1.16M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $155.00K 10-Q · filed 2023-08-09 | $309.00K 10-Q · filed 2023-08-09 | $463.00K derived: sum of 3 quarters · filed 2023-08-09 | $617.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $154.00K 10-Q · filed 2023-05-11 | $308.00K derived: sum of 2 quarters · filed 2023-05-11 | $462.00K derived: sum of 3 quarters · filed 2023-05-11 | $591.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $154.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $308.00K derived: sum of 2 quarters · filed 2023-03-15 | $437.00K derived: sum of 3 quarters · filed 2023-03-15 | $524.00K 10-K · filed 2023-03-15 |
| 2021-09-30 | $154.00K 10-Q · filed 2022-11-10 | $283.00K derived: sum of 2 quarters · filed 2022-11-10 | $370.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $129.00K 10-Q · filed 2022-08-11 | $216.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $87.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |